Evidence map›Paper›PMID 39407171›Full record

ArticleBMC public health2024

Post‑recovery symptoms of infected cases after Omicron pandemic: a quick online cross-sectional study based on C19-YRSm in China.

Xiao-Lei Ye, Ying Zhang, Xin-Hua Dai, Jun Gan, Yue Liu, Ai-Miao Liao, Li-Zhi Zhao, Chao Xie, Jing Zuo, Ping Wang and 8 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiao-Lei Ye *Center for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China. 1016751991@qq.com.
Ying Zhang *The First Affiliated Hospital of Xi 'an Jiaotong University in Shaanxi Province, Xi 'an, 710000, P. R. China.
Xin-Hua Dai *Center for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Jun Gan *Center for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Yue LiuCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Ai-Miao LiaoCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Li-Zhi ZhaoCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Chao XieCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Jing ZuoCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China.
Ping WangBaiyin Central Hospital, Baiyin, 730900, P. R. China.
Le-Le AiNanjing Bioengineering (Gene)Technology Center for Medicines, Zhongshan East Road, 293, Nanjing, 210002, P. R. China.
Yi-Fan ZhangDepartment of Stomatology, the 940th Hospital of Joint Logistic Support Force of the Chinese People's Liberation Army, Lanzhou, 730030, P. R. China.
Yan HuangThe Third People's Hospital of Chengdu (Affiliated Hospital of Southwest Jiaotong University), Chengdu, 610000, P. R. China.
Juan ZhangThe Lanzhou Enci Stomatological Hospital, Lanzhou, 730030, P. R. China.
Qing-Ming ShiCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China. shiqingming1980@qq.com.
Jun-Feng ZhengCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China. zheng-junfeng@126.com.
Wei-Long TanNanjing Bioengineering (Gene)Technology Center for Medicines, Zhongshan East Road, 293, Nanjing, 210002, P. R. China. njcdc@163.com.
Xiao-Bing HuCenter for Disease Control and Prevention in Western Theater Command, Lanzhou, 730030, P. R. China. 18981715872@189.cn.

Funding

Natural Science Foundation of Jiangsu Province BK20221196Social Development Project 2024YQZL02Social Development Project of Jiangsu Province BE2022682
6 · The paper itself

Abstract

backgroundThe post COVID-19 health condition of Chinese residents infected with Omicron is not clear after the change of epidemic prevention policies. This study aimed to clarify the epidemiology and associated factors about health status of rehabilitation patients.

methodsA quick questionnaire study based on C19-YRSm was conducted in mainland China through internet from May 1, 2023, to May 7, 2023. Chinese native speakers infected with Omicron variant agreed to participate were included. Persisting symptom and living habits were simultaneously inquired. Logistic regression analysis was used to identify the associated factors.

resultsIn this study 753 individuals were included. Of whom 57.90% were males, 89.38% did not seek medical service, 99.47% recovered within less than 120 days. Breathlessness (47.68%), cognitive impairment (44.89%), Anxiety/mood changes (33.20%), pain/discomfort (32.94%), fatigue or tiredness not improved by rest (32.27%) and post-exertional malaise (30.01%) were the top reported key symptoms. Less than 10% respondents reported functional limitations. The prevalence of fever was reported greater than that of other symptoms, with dry eyes at 14.87%, appetite change at 14.34%, and hair loss at 12.22%. Middle age (OR: 2.353, 95%CI: 1.171 ~ 4.729), underlying diseases (OR: 2.293, 95%CI: 1.216 ~ 4.324), severe key symptom (OR: 6.168, 95%CI: 1.376 ~ 27.642) and at least one other symptom (OR: 1.847, 95%CI: 1.225 ~ 2.718)during the recovery were the risk factors of poor overall health after infection (current overall health score <8; 74.10%), while daily exercise in recovery period (OR: 0.457, 95%CI: 0.229 ~ 0.913), a low-fat diet (OR: 0.600, 95%CI: 0.401 ~ 0.898) and the recovery time from 2 to 4 months (OR: 0.639, 95%CI: 0.445 ~ 0.918) were the protective factors.

conclusionThis is the first time to use the C19-YRSm scale to evaluate the health status in China. The study revealed prevalence of persistent symptoms within 120 days after Omicron onset.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultAgedChinaCross-Sectional StudiesFemaleHealth StatusHumansMaleMiddle AgedPandemicsSurveys and QuestionnairesYoung AdultC19-YRSmCOVID-19OmicronPost recovery

Identifiers

PMID39407171
PMCPMC11481264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.